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Abstract Children with severe chronic hemolytic anemia
or congenital erythroblastopenia are transfusion dependent.
Long-term transfusion therapy prolongs life but results in a
toxic accumulation of iron in the organs. The human body
cannot actively eliminate excess iron. Therefore, the use of
a chelating agent is required to promote excretion of iron.
So far, iron chelation has been done by subcutaneous
infusion of deferoxamine given over 10 h, 5–6 days per
week. Compliance is poor and chelation often insufficient.
Ferritin measurements and sometimes liver biopsies are
used to evaluate the iron burden in the body. At the present
time, new iron chelators that can be given orally are
available. Furthermore, magnetic resonance imaging (MRI)
assessment of tissue iron is a noninvasive and highly
reproducible method, which is able to quantitate organ iron
burden. In conclusion, iron overload can be measured more
accurately with noninvasive methods such as MRI. Defer-
asirox is a once-daily oral therapy for treating transfusional
iron overload, which improves patient compliance and
quality of life.
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Introduction
Children suffering from severe chronic hemolytic anemia
such as β-thalassemia, or congenital erythroblastopenia are
at risk of developing severe iron overload. Regular blood
transfusions are potentially life saving. However, every
single transfusion of one unit of blood brings 200 mg of
iron into the body of the recipient. Patients receiving 3 U
every 4 weeks (39 U per year) will accumulate 7.8 g of iron
by the end of the year, in addition to the amount absorbed
by the gut. The human body has no mechanism for active
excretion of excess iron. Repeated transfusions lead to
elevated iron levels that result in major organ damage.
Excess iron is deposited largely in the liver, spleen,
myocardium, and several endocrine organs. In young
patients, growth and maturation is slowed, and in all age
groups, liver disease, diabetes mellitus, and other compli-
cations develop. Once the body’s storage capacity is ex-
ceeded, free iron catalyses the formation of highly reactive
hydroxyl radicals, which cause membrane damage and
protein denaturation. This process leads to tissue damage
and ultimately to significant morbidity and mortality [3].
Measuring iron levels
(Table 1)
There are several methods of assessing body iron load.
As 90% of excess iron is deposited in the liver, most
techniques focus on measuring liver iron levels, and it is
widely accepted that liver iron content (LIC) provides an
accurate measure of whole-body iron concentration. The
invasive nature of the liver biopsy means that other markers
such as serum ferritin levels are frequently employed. Other
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resonance imaging (MRI) are also being assessed in order
to identify an accurate, low-risk, and convenient approach
to assessing patient iron status.
Ferritin
Serum ferritin is easily measured using a commercially
available kit. A ferritin constantly below 2,500 mg/l has
been shown to reduce the risk of cardiac complications, but
a target value of 1,000 mg/l is recommended. Factors such
as inflammation, ascorbate status, and hepatitis can affect
serum ferritin levels. Therefore, results should be inter-
preted with caution and a trend in the evolution of serial
measurements is a better index than day-to-day variation. In
patients with transfusion-dependent diseases, chelation
should be initiated after 10–20 blood transfusions or when
ferritin level rises above 1,000 mg/l.
Liver biopsy
LIC measurement is the most accurate method for assessing
body iron (Fig. 1). It also provides information about the
severity of the liver disease [8]. Liver samples can be
obtained by percutaneous or transjugular access. LIC
measurement from a needle biopsy has been associated
with a coefficient of variation of less than 10% in livers
with no advanced disease. However, it has been shown that
variability can be much higher in fibrotic and cirrhotic
livers. Values of LIC are expressed as milligrams of iron
per gram of dry liver weight.
Liver biopsy is an invasive technique that is associated
with some pain and at risk of hemorrhage and infection. It
is not indicated for routine assessment.
Superconducting quantum interference device (SQUID)
SQUID is capable of measuring very small changes in
magnetic flux. Iron stored as ferritin and hemosiderin is the
only relevant paramagnetic material in the human body.
The magnitude of paramagnetic response is directly related
to the amount of iron in a certain volume of tissue. This is a
noninvasive method, with a linear correlation with LIC
assessed by biopsy. However, equipment availability is
extremely limited [6].
Magnetic resonance imaging (MRI)
MRI measures tissue iron concentration indirectly by
detecting the paramagnetic influences of storage iron
(ferritin and hemosiderin) on proton resonance behavior.
With MRI, the transmitted signal is a microwave, which
excites water protons in the body to higher magnetic energy
states. As these water protons relax back to the unexcited
state, they emit microwaves that are received and inter-
preted by the scanner. Iron deposits act like little magnets
when placed in a strong magnetic field, disrupting
coherence among the protons and darkening the image
more quickly (Fig. 2)[ 13]. LIC determined using MRI
shows excellent correlation with that obtained from liver
biopsy. Furthermore, MRI has the ability to evaluate the
entire organ and gives more accurate measurement of LIC,
particularly in patients with heterogeneous iron content
(Fig. 3). It requires a dedicated imaging method and
equipment operator [13].
Iron chelation therapy
Within 1–2 years of initiation of regular blood transfusions,
iron starts to accumulate in the body. The use of a chelating
agent then becomes mandatory [6]. At the present time,
three different therapies are available (Table 2).
Baseline
After one year of deferasirox
Fig. 1 Liver biopsy (Perls stain): iron deposits are in blue. Courtesy
of B. Turlin, Pathology Department, University Hospital of Rennes
Table 1 Comparison of methods for evaluating iron overload
Invasive Cost Limitation Validation
Ferritin No Low Infection/
inflammation
Yes
LIC Yes Median Fibrosis/cirrhosis Yes
SQUID No High Not easily available Yes
MRI No High Dedicated person Yes
LIC liver iron content, SQUID superconducting quantum interference
device, MRI magnetic resonance imaging
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for iron chelation therapy. The long-term efficacy of this
approach has been demonstrated, limiting organ damage
and preventing premature death. Deferoxamine has a very
short half-life in plasma (5–10 min). Therefore, deferox-
amine is administered parenterally, either subcutaneously
8–12 h a day at least 5 days a week, or intravenously,
through a Port-a-Cath for continuous infusion. Low
compliance with the prolonged subcutaneous administra-
tion is the main reason of ineffective treatment. Toxic side
effects such as auditory, ocular, and neurotoxic abnormal-
ities are also drawbacks in the therapy.
Deferiprone (Ferriprox) is one of the hundreds of oral
chelators that have been tested. It was shown to have
comparable efficacy to subcutaneous deferoxamine. It has
been used as a monotherapy or in combination with
deferoxamine [7, 9]. It increases urinary excretion of iron
and is more effective than deferoxamine in the removal of
excess iron from the heart, as shown from MRI T2* studies
[1, 9, 10, 11]. Deferiprone and its iron complex are cleared
from the plasma with a half-life of 47–134 min. Therefore,
it should be taken three times a day. The major toxic side
effects are agranulocytosis, musculoskeletal and joint pains,
gastric intolerance, and zinc deficiency. Those side effects
are considered to be reversible. The combination of
deferoxamine and deferiprone is most effective when used
in the following way: deferiprone (80–110 mg/kg per day)
during the day and deferoxamine (40–60 mg/kg per day) at
least 3 nights a week. No new toxic effects have been
reported for the combination.
Deferasirox (Exjade) has been tested recently in clinical
trials [2, 3, 12]. Its long half-life makes it suitable for once-
daily oral administration. Efficacy at a dose of 20–30 mg/
kg per day is at least equivalent to that of deferoxamine
(≥35 mg/kg per day 5 days weekly) in a subgroup of
patients with higher hepatic iron burdens. The most
common toxic side effects are skin rash, increase in
transaminases and creatinine, and gastrointestinal symp-
toms such as nausea, vomiting, diarrhea, and abdominal
pain. The skin rash and gastrointestinal symptoms tend to
decrease spontaneously with time and an increase in
creatinine may require a dose adjustment. The increase in
transaminases is usually linked to an insufficient dose of
deferasirox and an increase in the hepatic iron overload. A
higher dose of deferasirox will result in an improvement in
transaminases.
Discussion
Chronic iron overload due to blood transfusions leads to
significant morbidity and early mortality unless adequate
chelation therapy is administered. Deferoxamine is the
reference chelation therapy, but compliance to the treatment
is often poor because it must be administered by prolonged
subcutaneous or intravenous infusion. Oral chelators are
now available: Deferasirox has the advantage of being
administered once daily, with a low toxicity profile.
Furthermore, its cost effectiveness has also been demon-
strated [5]. MRI has emerged as the dominant technique by
which to evaluate iron overload because of its sensitivity,
reproducibility, and ability to image multiple organs in the
body during a single imaging session.
Fig. 3 Gradient echo imaging illustrating discordant iron loading of
the liver and heart. a Heavy liver iron loading (dark tissue) with heart
sparing image. b Heavy cardiac iron loading with no liver deposition.
From [13]
Fig. 2 Gradient echo images of liver collected by J. Wood [13] at four
different echo times. The top four images were collected from a patient
having a liver iron of 6 mg/g. The bottom four images were collected
from a normal volunteer. All images darken as the echo time (TE)
lengthens, but the iron-heavy tissue darkens faster. The half-life of this
process is called T2* and the rate is called R2* (R2*=1,000/T2*)
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Deferiprone
(Ferriprox)
Deferasirox
(Exjade)
Route of
administration
Subcutaneous or
intravenous
Oral Oral
Half-life 20 min 2–3h 8 –16 h
Routes of iron
excretion
Urine/stool Urine stool
Dose range 20–60 mg/kg per day 50–60 mg/kg per day 20–30 mg/kg/day
Guidelines for
monitoring
therapy
Audiometry and
eye exams annually
Complete blood count
weekly; ALT level
monthly for first
3–6 months then every
6 months
Serum creatinine level
monthly; ALT level monthly
Serum ferritin Serum ferritin Serum ferritin
Assessment of liver
iron annually
Assessment of liver
iron annually
Assessment of liver
iron annually
Assessment of
cardiac iron
annually after
10 years of age
Assessment of cardiac
ron annually after
10 years of age
Assessment of cardiac
iron annually after
10 years of age
Advantages Long-term
experience
Orally active Orally active
Effective in
maintaining normal
or near-normal iron
stores
Safety profile well
established
Once-daily administration
Reversal of cardiac
disease with
intensive therapy
Enhanced removal of
cardiac iron
Demonstrated equivalency
to deferoxamine at
higher doses
May be combined
with deferiprone
May be combined with
deferoxamine
Trials in several
hematologic disorders
Disadvantages Requires parenteral
infusion
May not achieve negative
iron balance in all
patients at 75 mg/kg
per day
Limited long-term data
Ear, eye, bone
toxicity
Risk of agranulocytosis Need to monitor renal function
Poor compliance May not achieve negative
iron balance in all patients
at highest dose
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